Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Authors:
- Evangelia RazisEREvangelia Razis
- Evangelos BriasoulisEBEvangelos Briasoulis
- Eleni VrettouEVEleni Vrettou
- Dimosthenis V SkarlosDSDimosthenis V Skarlos
- Dimitrios PapamichaelDPDimitrios Papamichael
- Ioannis KostopoulosIKIoannis Kostopoulos
- Epaminontas SamantasESEpaminontas Samantas
- Ioannis XanthakisIXIoannis Xanthakis
- Mattheos BobosMBMattheos Bobos
- Eleni GalanidiEGEleni Galanidi
- Maria BaiMBMaria Bai
- Ioanna GikontiIGIoanna Gikonti
Open Access
- 13 August 2008
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 1-10
Abstract
The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been approved for the treatment of metastatic CRC, however tumor response to cetuximab has not been found to be associated with EGFR over-expression by immunohistochemistry (IHC). The aim of this study was to explore EGFR and the downstream effector phosphatase and tensin homologue deleted on chromosome 10 (PTEN) as potential predictors of response to cetuximab. CRC patients treated with cetuximab by the Hellenic Cooperative Oncology group, whose formalin-fixed paraffin-embedded tumor tissue was available, were included. Tissue was tested for EGFR and PTEN by IHC and fluorescence in situ hybridization (FISH). Eighty-eight patients were identified and 72 were included based on the availability of tissue blocks with adequate material for analysis on them. All patients, except one, received cetuximab in combination with chemotherapy. Median follow-up was 53 months from diagnosis and 17 months from cetuximab initiation. At the time of the analysis 53% of the patients had died. Best response was complete response in one and partial response in 23 patients. In 16 patients disease stabilized. Lack of PTEN gene amplification was associated with more responses to cetuximab and longer time to progression (p = 0.042). PTEN could be one of the molecular determinants of cetuximab response. Due to the heterogeneity of the population and the retrospective nature of the study, our results are hypothesis generating and should be approached with caution. Further prospective studies are needed to validate this finding.Keywords
This publication has 24 references indexed in Scilit:
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase InhibitorsClinical Cancer Research, 2007
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidinesJournal of Clinical Oncology, 2006
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization studyLaboratory Investigation, 2005
- Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implicationsAnnals of Oncology, 2005
- Molecular Determinants of Cetuximab EfficacyJournal of Clinical Oncology, 2005
- Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- In Reply:Journal of Clinical Oncology, 2004